Loading…
Based on limited metadata, this Warning Letter issued to Lymol Medical Corp on January 8, 2019 concerns drug products under FDA jurisdiction. While the specific violations cannot be determined without access to the full letter text, the warning indicates regulatory concerns regarding the company's drug manufacturing, marketing, or compliance practices. The letter represents formal FDA enforcement action requiring the company's response to address identified deficiencies in drug product operations or quality standards.